What was Johnson & Johnson's overall sales performance in the third quarter of fiscal year 2021?

Johnson & Johnson reported a 10.7% increase in worldwide sales to $23.3 billion for the third quarter of fiscal 2021, compared to $21.1 billion in the same period of fiscal 2020. This growth was primarily driven by an operational increase of 9.9%, with currency fluctuations contributing an additional 0.8%.

Which business segments contributed most to the sales growth?

The Pharmaceutical segment was a key growth driver, with sales increasing by 13.8% operationally. The Medical Devices segment also showed a strong recovery, with sales up 8.0% operationally, reflecting a rebound in procedural volumes. The Consumer Health segment also saw positive sales growth of 5.3% operationally, despite facing significant litigation expenses.

How are the ongoing litigation matters impacting Johnson & Johnson's financial results?

Johnson & Johnson is involved in significant litigation, notably concerning talc products, opioids, and Risperdal. These matters resulted in substantial charges, particularly impacting the Consumer Health segment (talc litigation) and the Pharmaceutical segment (Risperdal settlement). While these have affected segment profitability, the company has accrued significant reserves and continues to manage these liabilities.

What is the company's cash flow and liquidity position?

Johnson & Johnson generated $17.7 billion in cash flow from operations for the first nine months of fiscal 2021, a significant increase from the prior year. The company maintained a strong liquidity position with $17.6 billion in cash and cash equivalents and $13.4 billion in marketable securities as of October 3, 2021.

JNJ 10-Q Filed Oct 29, 2021

Summary

Johnson & Johnson (JNJ) reported strong financial results for the third quarter and first nine months of fiscal year 2021. Sales increased across all segments, driven by robust performance in the Pharmaceutical and Medical Device divisions, with notable growth in key therapeutic areas like Oncology and Immunology, as well as strong recovery in Medical Device procedural volumes. While the company experienced a net loss in the Consumer Health segment due to significant litigation expenses, particularly related to talc, the overall financial health remains robust. The company generated substantial operating cash flow, allowing for continued investment in research and development, dividend payments, and share repurchases. JNJ also demonstrated effective management of its debt, with a net debt position improving from the previous year. The company remains focused on navigating ongoing litigation and regulatory environments while pursuing strategic growth initiatives across its diverse business units.

Key Highlights

1Worldwide sales increased by 10.7% to $23.3 billion in the third quarter of fiscal 2021 compared to the prior year, driven by operational growth of 9.9% and favorable currency impacts.
2Nine-month worldwide sales grew by 14.7% to $69.0 billion, with operational growth of 12.4% and a positive currency impact of 2.3%.
3The Pharmaceutical segment showed strong performance with third-quarter sales up 13.8% operationally, driven by Oncology, Immunology, and the COVID-19 vaccine.
4The Medical Devices segment experienced a significant recovery, with third-quarter sales up 8.0% operationally, reflecting the rebound in global procedural volumes.
5Despite a net loss in the Consumer Health segment due to increased litigation expenses (primarily talc), the segment's total sales grew by 5.3% operationally in the third quarter.
6The company generated strong operating cash flow of $17.7 billion for the first nine months of 2021.
7Johnson & Johnson has significant ongoing litigation, including talc, opioid, and Risperdal settlements, which impacted profitability in the Consumer Health and Pharmaceutical segments respectively, but has established reserves and is actively managing these exposures.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Oct 3, 2021

Summary

Key Highlights

Frequently Asked Questions